Establishment Labs (ESTA) Stock Price, News & Analysis

Company Overview

Establishment Labs Holdings Inc. is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification. In addition to its core breast implant offerings, Establishment Labs is actively advancing a pipeline of complementary aesthetic and regenerative technologies aimed at expanding its footprint in minimally invasive and soft-tissue restoration procedures.

Founded in Costa Rica in 2004, Establishment Labs has grown into an international enterprise with manufacturing facilities in Central America and distribution in more than 70 markets across North America, Latin America, Europe and the Asia-Pacific region. The company further broadened its capital access through a special purpose acquisition merger, resulting in its listing on the Nasdaq exchange in mid-2020.

Leadership is anchored by founder and Executive Chairman Mauricio Cárdenas, whose entrepreneurial vision has guided the company since inception, alongside Chief Executive Officer Juan José Chacón, who oversees global operations, strategy and continued product innovation.

Key Stats

• Today's Range: $68.77 to $71.86
• 50-Day Range: $54.69 to $74.63
• 52-Week Range: $33.35 to $83.31
• Volume: 284,683 shs
• Average Volume: 503,122 shs
• Market Capitalization: $2.04 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $87.14
• Consensus Rating: Moderate Buy

Establishment Labs Stock Analysis - MarketRank™

Establishment Labs scored higher than 66% of companies evaluated by MarketBeat, and ranked 350th out of 868 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.9 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Establishment Labs has received a consensus rating of Moderate Buy. The company's average rating score is 2.63, and is based on no strong buy ratings, 6 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Establishment Labs has a consensus price target of $87.14, representing about 25.8% upside from its current price of $69.25.

Amount of Analyst Coverage

Establishment Labs has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Establishment Labs are expected to grow in the coming year, from ($1.07) to $0.14 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Establishment Labs is -46.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Establishment Labs is -46.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Establishment Labs has a P/B Ratio of 85.49. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

13.79% of the float of Establishment Labs has been sold short.

Short Interest Ratio / Days to Cover

Establishment Labs has a short interest ratio ("days to cover") of 5.68.

Change versus previous month

Short interest in Establishment Labs has recently decreased by 3.32%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Establishment Labs does not currently pay a dividend.

Dividend Growth

Establishment Labs does not have a long track record of dividend growth.

News and Social Media

• Score: 3.5 / 5
• News Sentiment: 1.58

News Sentiment

Establishment Labs has a news sentiment score of 1.58. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.84 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Establishment Labs this week, compared to 3 articles on an average week.

Search Interest

1 people have searched for ESTA on MarketBeat in the last 30 days.

Company Ownership

• Score: 1.8 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Establishment Labs insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $22,854,538.00 in company stock.

Percentage Held by Insiders

9.99% of the stock of Establishment Labs is held by insiders.

Percentage Held by Institutions

72.91% of the stock of Establishment Labs is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 5/07/2026
• Today: 6/01/2026
• Next Earnings (Estimated): 8/06/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Medical Services
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:ESTA
• CIK: 1688757
• Web: www.establishmentlabs.com
• Phone: (062) 434-2400
• Fax: N/A
• Employees: 1,004
• Year Founded: 2004

Price Target and Rating

• Average Price Target for Establishment Labs: $87.14
• High Price Target: $100.00
• Low Price Target: $74.00
• Potential Upside/Downside: +25.8%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.63
• Research Coverage: 8 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.49)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$51.06 million
• Net Margins: -19.05%
• Pretax Margin: -22.35%
• Return on Equity: -218.77%
• Return on Assets: -12.31%

Debt

• Debt-to-Equity Ratio: 16.82
• Current Ratio: 2.96
• Quick Ratio: 1.91

Sales & Book Value

• Annual Sales: $211.08 million
• Price / Sales: 9.66
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.81 per share
• Price / Book: 85.49

Miscellaneous

• Outstanding Shares: 29,430,000
• Free Float: 26,490,000
• Market Cap: $2.04 billion
• Optionable: Optionable
• Beta: 1.11